胰腺导管腺癌 (PDAC) 是最常见的胰腺癌类型，也是最具侵袭性的肿瘤之一，5 年生存率低于 11%。预测表明，到 2030 年，它将成为癌症相关死亡的第二大原因。 PDAC 具有导致其预后不良的独特特征：(i) 诊断较晚，(ii) 异质且复杂的突变景观，(iii) 高转移潜力，(iv) 致密纤维化基质，(v) 免疫抑制微环境，以及 (vi) 高转移性。对治疗的抵抗。越来越多的证据表明酪氨酸激酶受体 TAM（Tyro3、AXL、MerTK）家族在 PDAC 启动和进展中发挥作用。本综述旨在描述 TAM 受体对 PDAC 定义标志的影响，并讨论使用这些蛋白质作为 PDAC 早期诊断的新型生物标志物和 PDAC 精准治疗的靶点的潜在未来方向，PDAC 是一项紧迫的未满足的临床需求。版权所有 © 2024 作者（ s）。由 Elsevier B.V. 出版。保留所有权利。

Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.